CA2564092A1 - Procedes et compositions pour le traitement des maladies polykystiques - Google Patents
Procedes et compositions pour le traitement des maladies polykystiques Download PDFInfo
- Publication number
- CA2564092A1 CA2564092A1 CA002564092A CA2564092A CA2564092A1 CA 2564092 A1 CA2564092 A1 CA 2564092A1 CA 002564092 A CA002564092 A CA 002564092A CA 2564092 A CA2564092 A CA 2564092A CA 2564092 A1 CA2564092 A1 CA 2564092A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- agent
- polynucleotide
- gene
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 9
- 201000010099 disease Diseases 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract 17
- 230000014509 gene expression Effects 0.000 claims abstract 14
- 210000001519 tissue Anatomy 0.000 claims abstract 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract 6
- 230000004071 biological effect Effects 0.000 claims abstract 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract 3
- 230000003902 lesion Effects 0.000 claims abstract 3
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims description 5
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims description 5
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 150000003384 small molecules Chemical group 0.000 claims 5
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 108091008103 RNA aptamers Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000004481 post-translational protein modification Effects 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 102100031168 CCN family member 2 Human genes 0.000 claims 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 230000037416 cystogenesis Effects 0.000 abstract description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 abstract 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 208000031513 cyst Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 206010019646 Hepatic cyst Diseases 0.000 description 1
- 208000000407 Pancreatic Cyst Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56667004P | 2004-04-29 | 2004-04-29 | |
| US60/566,670 | 2004-04-29 | ||
| US59038504P | 2004-07-22 | 2004-07-22 | |
| US60/590,385 | 2004-07-22 | ||
| PCT/US2005/014982 WO2005117941A2 (fr) | 2004-04-29 | 2005-04-29 | Procedes et compositions pour le traitement des maladies polykystiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2564092A1 true CA2564092A1 (fr) | 2005-12-15 |
Family
ID=35463346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002564092A Abandoned CA2564092A1 (fr) | 2004-04-29 | 2005-04-29 | Procedes et compositions pour le traitement des maladies polykystiques |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1740221A4 (fr) |
| JP (1) | JP2007535562A (fr) |
| BR (1) | BRPI0510367A (fr) |
| CA (1) | CA2564092A1 (fr) |
| MX (1) | MXPA06012446A (fr) |
| WO (1) | WO2005117941A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| EP1808694A1 (fr) * | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Procédé de diagnostic d'une maladie polykystique des reins |
| WO2008051502A1 (fr) * | 2006-10-19 | 2008-05-02 | Genzyme Corporation | Dérives de purine pour traitement de maladies cystiques |
| EP2331141B1 (fr) | 2008-08-25 | 2016-01-06 | Excaliard Pharmaceuticals, Inc. | Oligonucléotides antissens dirigés contre le facteur de croissance des tissus conjonctifs et utilisation de ceux-ci |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| MX365647B (es) | 2011-02-02 | 2019-06-10 | Excaliard Pharmaceuticals Inc | El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas. |
| JP5995207B2 (ja) * | 2014-11-28 | 2016-09-21 | 学校法人 学習院 | 含ホウ素ポルフィリン誘導体 |
| KR102288447B1 (ko) * | 2018-12-28 | 2021-08-10 | 서울대학교산학협력단 | Ctgf 검출용 제제를 포함하는 다낭신의 진단용 조성물 및 이의 이용 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789189A (en) * | 1993-09-24 | 1998-08-04 | The Regents Of The University Of California | Inhibition of cyst formation by cytoskeletal specific drugs |
| WO1999033878A1 (fr) * | 1997-12-25 | 1999-07-08 | Japan Tobacco Inc. | Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales |
| US6875747B1 (en) * | 1999-05-24 | 2005-04-05 | Avi Bio Pharma, Inc. | Antisense to c-myc for treatment of polycystic kidney disease |
| AU2002326939A1 (en) * | 2001-09-18 | 2003-04-01 | Fibrogen, Inc. | Methods of assaying connective tissue growth factor |
| US6965025B2 (en) * | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
-
2005
- 2005-04-29 EP EP05804799A patent/EP1740221A4/fr not_active Withdrawn
- 2005-04-29 JP JP2007511046A patent/JP2007535562A/ja not_active Withdrawn
- 2005-04-29 CA CA002564092A patent/CA2564092A1/fr not_active Abandoned
- 2005-04-29 BR BRPI0510367-3A patent/BRPI0510367A/pt not_active IP Right Cessation
- 2005-04-29 MX MXPA06012446A patent/MXPA06012446A/es not_active Application Discontinuation
- 2005-04-29 WO PCT/US2005/014982 patent/WO2005117941A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005117941A3 (fr) | 2006-05-18 |
| BRPI0510367A (pt) | 2007-11-06 |
| JP2007535562A (ja) | 2007-12-06 |
| EP1740221A2 (fr) | 2007-01-10 |
| EP1740221A4 (fr) | 2009-01-07 |
| WO2005117941A2 (fr) | 2005-12-15 |
| MXPA06012446A (es) | 2007-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alexiou et al. | RAGE: a multi-ligand receptor unveiling novel insights in health and disease | |
| RU2015147287A (ru) | Гуманизированные антитела против axl | |
| US20210230300A1 (en) | Inhibitors of shp2 | |
| AU2024227435A1 (en) | Anti-age antibodies for treating neurodegenerative disorders | |
| KR20050071564A (ko) | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 | |
| JP2008529489A5 (fr) | ||
| EP4069301A1 (fr) | Inhibiteurs de shp2 | |
| JP2010514454A5 (fr) | ||
| JP7410211B2 (ja) | 望ましくない細胞増殖に関係する疾患の処置のための薬剤 | |
| UA126571C2 (uk) | Антитіло до cd73 та його застосування | |
| CA3074993A1 (fr) | Composition pour prevenir ou traiter les maladies liees au facteur de necrose tumorale (tnf) et methode d'inhibition de l'activite du tnf | |
| CA2564092A1 (fr) | Procedes et compositions pour le traitement des maladies polykystiques | |
| CA2695972A1 (fr) | Modulation par des immunoglobulines intraveineuses (ivig) de chimiokines pour le traitement de la sclerose en plaques, de la maladie d'alzheimer et de la maladie de parkinson | |
| JP2023501686A (ja) | 線維性疾患の予防及び処置のための抗クローディン－１モノクローナル抗体。 | |
| TWI710575B (zh) | 人類抗-fgfr4抗體 | |
| JP6802342B2 (ja) | 腎症を処置する方法 | |
| WO2017013061A1 (fr) | Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci | |
| KR20230173734A (ko) | RGMa 결합 단백질 및 그 사용 | |
| US20250145708A1 (en) | Epitope of Regulatory T Cell Surface Antigen and Antibody Specifically Binding Thereto | |
| CA3128420A1 (fr) | Anticorps monoclonal anti-syndrome antisynthetase humanise | |
| Pankiewicz et al. | APOE genotype differentially modulates effects of anti-Aβ, passive immunization in APP transgenic mice | |
| US20150376281A1 (en) | Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes | |
| Moreno et al. | Role of chemokines in proteinuric kidney disorders | |
| JP2010524847A5 (fr) | ||
| JP2006523087A (ja) | 抗体（“１１ｃ７”）抗ｎｏｇｏａおよびその薬学的使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |